iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Biotech IPOs have gained ground in 2026, but technology IPOs have not stopped. PwC counted 22 biotech IPOs raising $6.9 billion through September 30, compared with seven IPOs raising $1.4 billion during all of 2025. Meanwhile, the broader U.S. IPO market slowed late in the third quarter, and a single unusually large technology offering made the quarter’s total look much stronger than most issuers’ experience.
What does “biotech charge ahead as tech deals stall” mean?
It describes a selective biotech reopening amid a less buoyant, more concentrated IPO market—not a clean, like-for-like victory over technology. Biotech’s year-to-date IPO count and proceeds rose sharply from 2025, while third-quarter reports point to weaker broad-market momentum and healthcare’s prominence. But technology companies continued to list, and the available figures cover different periods and deal definitions.
PwC reported 22 biotech IPOs and $6.9 billion in proceeds through September 30, 2026, versus seven IPOs and $1.4 billion for all of 2025. That comparison is useful because it shows the scale of the rebound, but the 2026 figure covers only nine months while the 2025 figure covers a full year.
Recommended Free Tools
Why are biotech IPOs doing better while tech IPOs are slowing down?
Biotech can reach the public market when investors see evidence that a drug program has advanced enough to justify its risk. Advisers cited clinical data, experienced management, a credible regulatory path and a large addressable market as features that helped companies attract buyers. Preclinical companies, which have not yet produced clinical evidence in people, remained largely shut out, according to ION Analytics’ reporting.
#1 Best Overall
ION Analytics also reported adviser explanations for the renewed interest: scientific progress continued during the market downturn; healthcare specialists and some generalist investors returned; successful aftermarket performance encouraged participation in follow-on offerings; and renewed M&A activity provided exits and recycled capital. A quoted adviser also pointed to pharmaceutical companies’ need to replenish pipelines ahead of patent expirations. These are explanations offered by market participants, not proof that any one factor caused the rebound.
The contrast with technology is partly about timing and market conditions. Renaissance Capital’s October 1 review described a Q3 market that fell short of expectations, citing concerns about AI spending, a 19-year high in bond yields, resumed rate hikes and late-quarter postponements. Those pressures affected the broad IPO environment; they do not show that every technology issuer was unable to go public.
Rank #2
What the third-quarter IPO totals show—and hide
Renaissance Capital counted 30 U.S. IPO listings and $32.8 billion in Q3 2026 proceeds. SK hynix’s $26.5 billion U.S. offering accounted for most of that money; excluding it, proceeds were $6.2 billion. The headline total therefore reflects one exceptionally large cross-border technology offering rather than broad strength across issuers.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Separately, ICR Capital reported that healthcare represented 45% of Q3 IPO issuance by count, compared with 15% for technology. These sector shares and Renaissance Capital’s overall market totals are not necessarily based on identical universes or definitions. They support a description of Q3 as healthcare-led by count and slower than expected overall, not a precise ranking of biotech against technology using a single consistent dataset.
Technology IPOs were still happening
Wilson Sonsini counted 37 U.S.-based technology and life-sciences IPOs or direct listings above $75 million in H1 2026, compared with 18 in H1 2025. Within its H1 2026 data, it counted 15 technology IPOs and 16 life-sciences IPOs. The life-sciences group included six biotech and six pharmaceutical listings.
This is evidence that technology IPOs continued in the first half and that the combined technology-and-life-sciences group grew year over year. It does not establish how technology performed in Q3. Nor should the figures be treated as a direct comparison with PwC’s biotech-only total: Wilson Sonsini uses a $75 million threshold, includes direct listings in its combined count and classifies deals differently.
Biotech issuers reaching the market tended to be later-stage
The reopening has not been equally accessible to every biotech company. In its May 31, 2026 snapshot of 11 biopharmaceutical IPOs, Driehaus Capital Management reported that 55% had a Phase 2 lead asset and 36% had a Phase 3 lead asset. The remaining share should not be inferred to represent a particular stage without the source’s full classifications.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesThat small, dated cohort is consistent with ION Analytics’ reporting that Phase 2, late Phase 2 and Phase 3 companies were better positioned than preclinical issuers. It is not a full-year market estimate. Driehaus also reported a mean deal size of $345.2 million and a median of $345.0 million for that same cohort, using data accessed from Jefferies Healthcare Equity Capital Markets.
Best Value
Why biotech IPO counts and proceeds can disagree
Different publishers count different things: biotech alone or broader life sciences; IPOs only or IPOs plus direct listings; domestic offerings or cross-listings; and deals above or below particular size thresholds. Counts and proceeds also move differently: a small number of very large offerings can lift dollars raised without a comparable increase in the number of issuers.
For example, ION Analytics, citing Dealogic, reported 21 U.S. biotech IPOs raising $7.85 billion year to date as of August 19, 2026. PwC later reported 22 biotech IPOs and $6.9 billion through September 30. Because the publishers’ definitions may differ, these snapshots should not be combined or read as evidence that proceeds fell between August and September.
When comparing market claims, check the measurement period, sector definition, inclusion threshold, whether direct listings count, and whether the figure represents deal count or proceeds. For biotech, clinical stage matters too: a market that welcomes later-stage issuers may still be effectively closed to companies without human clinical evidence.
What investors and founders should take from the trend
- For founders: the window appears selective, not universally open. Clinical validation, a clear regulatory path, credible leadership and a sufficiently large market were cited as factors supporting demand.
- For investors: aggregate IPO proceeds do not describe the typical deal. In Q3, the SK hynix offering dominated the total, while proceeds excluding it were much lower.
- For anyone tracking sector momentum: compare like with like. A biotech-only year-to-date count cannot be directly ranked against technology’s Q3 share or a combined H1 listing count.
Cooley global capital markets co-chair Charlie Kim summed up the separation between scientific and financial cycles in comments to ION Analytics: “Even when IPO markets slow down or close, science continues to go.” The point is not that strong science guarantees an IPO, but that company development can continue while public-market access tightens.
Quick Recap
Sources and scope
- PwC, IPO Watch — biotech IPO count and proceeds through September 30, 2026, compared with 2025.
- Renaissance Capital — U.S. Q3 listings, proceeds and market conditions, reviewed October 1, 2026.
- Wilson Sonsini — H1 2026 technology and life-sciences IPOs and direct listings above $75 million.
- ION Analytics — adviser commentary and Dealogic’s August 19 biotech snapshot.
- Driehaus Capital Management — May 31 cohort snapshot of 11 biopharmaceutical IPOs.
- ICR Capital — Q3 sector shares by issuance count.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
